Whalesbook
Axis Securities ne Jubilant Ingrevia par coverage shuru ki hai aur seedha 'Buy' rating de di, saath mein ₹800 ka price target bhi set kiya hai. Ye sab isliye kyunki company ab specialty chemicals aur contract manufacturing par zyada focus kar rahi hai, jismein capacity bhi badhai hai aur naye products ka pipeline bhi mast hai.
Is positive report ke baad, Jubilant Ingrevia ke shares 22 April 2026 ko dopahar tak lagbhag 4.45% badh gaye, ₹701.90 ke intraday high tak pahunch gaye. Axis Securities ka kehna hai ki company apni commodity focus se specialty player banne ke liye 'Pinnacle345' initiative par kaam kar rahi hai. Isse FY30 tak revenue aur EBITDA mein zabardast growth ka target hai. Pichhle teen saal mein company ne lagbhag ₹2,000 crore ka capex kiya hai, jisse multipurpose plants aur Vitamin B3 production badha hai. China mein overcapacity kam hone aur favourable trade deals se bhi export mein help mil rahi hai. Current valuation, Price-to-Earnings (P/E) ratio lagbhag 39.9x par, specialty chemical peers ke comparison mein theek lag raha hai. Is dauran Nifty50 index 0.66% gira, jo Jubilant Ingrevia ki performance ko aur highlight karta hai. Axis Securities ne ₹800 ka target diya hai, jo ₹659 par closing price se lagbhag 21% zyada hai.
Company ke growth pipeline mein 16 confirmed molecules hain aur 100+ potential projects hain, jisse ₹3,500 crore tak ka peak revenue aa sakta hai. Jubilant Ingrevia ne $300 million ka agrochemical contract manufacturing deal bhi secure kiya hai. Contract manufacturing mein India mein competition kaafi hai, jaise Syngene International, Piramal Pharma Solutions, aur Divi's Laboratories jaise bade players hain. Indian contract manufacturing market 2033 tak $55.5 billion tak pahunchne ki ummeed hai, jo 13.2% ke annual rate se grow karega. Specialty chemicals sector innovation aur tailored solutions se chal raha hai. Haalanki, pichhle teen saal mein Indian Chemicals industry ki earnings 4.3% giri hai, lekin aage earnings 20% tak grow hone ka forecast hai. Agar pichhle trends dekhein toh, 'Buy' rating ke baad stocks ne acchi performance dikhai hai. Jaise March 2021 mein ₹240 par 'Buy' rating ke baad stock saat mahine mein 3.5 times se zyada badha tha. Haal hi mein, Anand Rathi aur Kotak Securities ne bhi 'Buy' rating aur ₹975 aur ₹870 ke targets diye hain. Generally, analysts ka average target lagbhag ₹919.50 hai.
Itni achhi analyst report aur growth targets ke bawajood, Jubilant Ingrevia ke ambitious plans mein execution risks kaafi hain. 'Pinnacle345' strategy ka aim FY30 tak revenue ko triple aur EBITDA ko quadruple karna hai, jo bahut challenging goal hai aur iske liye perfect operational execution chahiye. Management ka aim hai ki paanch saal mein EBITDA margins 18-20% tak pahunch jayen, lekin Q2FY26 mein margin sirf 13% tha, jo target se kaafi kam hai. Return on Capital Employed (ROCE) ko FY27-28 tak current ~11.2% se badha kar 15% se upar le jaana hai, jiske liye capital ka smart use karna padega. Company ka P/E ratio 40x ke aas paas hai, jo chemical sector ke liye thoda zyada hai, jahan earnings mein volatility aur cycles aate rehte hain. Specialty chemicals mein diversification ke bawajood, company abhi bhi cyclical intermediate products par depend karti hai. Pichhle kuch issues, jaise FY20-21 ke liye ₹6.63 crore ka CGST demand aur kuch facilities par environmental concerns, ye batate hain ki compliance aur oversight par dhyaan dena zaroori hai. Contract manufacturing aur specialty chemicals dono mein zabardast competition hai, jismein continuous innovation aur cost control karna padega.
Overall, analysts Jubilant Ingrevia ko lekar positive hain. Stock ko cover karne wale chah analysts mein se sab 'Strong Buy' rating de rahe hain. Average 12-month price target ₹919.50 hai, jo ₹1,100 (high) se lekar ₹657 (low) tak vary karta hai. Axis Securities (₹800) aur Anand Rathi (₹975) ke targets bhi current levels se potential upside dikhate hain. Ye optimism specialty chemicals, nutrition, aur contract manufacturing se hone wali earnings growth ke karan hai. Jubilant Ingrevia khud bhi aane wale samay mein 27.2% annual earnings growth, 14.5% revenue growth, aur 26.7% EPS growth ka projection de raha hai.